Market research
METROPOLIS.NSE Metropolis Healthcare Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 112B
- P/E ratio
- 56.17
- Analyst target
- 666.0526
- Dividend yield
- 0.0%
- Beta
- 0.2
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- INE112L01020
- Market cap
- 112B
- P/E ratio
- 56.17
- Analyst target
- 666.0526
- Dividend yield
- 0.0%
- Beta
- 0.2
About
About Metropolis Healthcare Limited
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnostic services for oncology, chronic and infectious diseases, gastroenterology, neurology, nephrology, and women and child health, as well as various health checkup and laboratory services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, mobile app, website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.
Research context
Metropolis Healthcare Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the METROPOLIS.NSE discussion.
5 years, 6 months ago
Metropolis Healthcare Limited is currently in a long term uptrend where the price is trading 35.2% above its 200 day moving average.
From a valuation standpoint, the stock is 152.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12.1.
Metropolis Healthcare Limited's total revenue rose by 23.3% to $3B since the same quarter in the previous year.
Its net income has increased by 39.2% to $586M since the same quarter in the previous year.
Finally, its free cash flow fell by 8.8% to $935M since the same quarter in the previous year.
Based on the above factors, Metropolis Healthcare Limited gets an overall score of 3/5.